← back to search

Simon A. Jones

Cardiff University · GB
Area of research
Immunology · Oncology
Research interest
Research interests include Cytokine Signaling Pathways and Interactions, Immune Response and Inflammation, Rheumatoid Arthritis Research and Therapies, and Immune Cell Function and Interaction.
h-index
72
citations
22,275
works
269
NIH funding
primary concept
Medicine
email

Recent publications

Developing interferon-β as a safe in vivo experimental-medicine model of human inflammation.
2026cited by 0position: contributordoi
Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities
Biotechnology Advances 2025cited by 7position: middledoi
Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities.
2025cited by 3position: contributordoi
More and more pleiotropy within the IL-6 family of cytokines.
2025cited by 3position: contributordoi
12/15-lipoxygenase orchestrates murine wound healing via PPARγ-activating oxylipins acting holistically to dampen inflammation.
2025cited by 3position: contributordoi
Maternal physiological parameters and routine laboratory tests to screen for maternal sepsis: an observational cohort study
International Journal of Obstetric Anesthesia 2025cited by 2position: middledoi
Maternal physiological parameters and routine laboratory tests to screen for maternal sepsis: an observational cohort study.
2025cited by 1position: contributordoi
Developing Interferon-β as a safe in-vivo experimental-medicine model of human inflammation
2025cited by 1position: contributordoi
Discrete cytokine signaling networks instruct distinct synovial pathotypes in inflammatory arthritis
2025cited by 0position: contributordoi
The Coronavirus Envelope Is Modulated by Host Inflammation and Enriched in Bioactive Lipids Required for Replication
2025cited by 0position: contributordoi
Interleukin-6 elevates thrombosis via pro-coagulant phospholipids from platelet 12-lipoxygenase in rheumatoid arthritis
2025cited by 0position: contributordoi
12/15-Lipoxygenase orchestrates murine wound healing via PPARγ-activating oxylipins acting holistically to dampen inflammation
2025cited by 0position: contributordoi
P112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis
Lara D. Veeken 2025cited by 0position: lastdoi
Risk factors for infection and outcomes in infants with neonatal encephalopathy: a cohort study.
2024cited by 3position: contributordoi
IL-6 and IL-27 negatively regulate CRTAM-expressing CD4 <sup>+</sup> T-cells associated with lymphoid-driven synovitis
2024cited by 0position: contributordoi
The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study.
2023cited by 18position: contributordoi
Inhibitory IL-10-producing CD4&lt;sup&gt;+&lt;/sup&gt; T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1.
2023cited by 9position: contributordoi
Th1 Cells Alter the Inflammatory Signature of IL-6 by Channeling STAT Transcription Factors to Alu-like Retroelements.
2023cited by 5position: contributordoi
Tracking the Host Response to Infection in Peritoneal Models of Acute Resolving Inflammation.
2023cited by 0position: contributordoi
Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation
Nature Communications 2022cited by 88position: middledoi
Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation.
2022cited by 60position: contributordoi
Making sense of IL-6 signalling cues in pathophysiology.
2022cited by 22position: contributordoi
Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to <i>Alu</i> -like retroelements
2022cited by 0position: contributordoi
Is IL-6 a key cytokine target for therapy in COVID-19?
2021cited by 110position: contributordoi
Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T<sub>H</sub>17 cell expansion.
2021cited by 20position: contributordoi
Unravelling the broader complexity of IL-6 involvement in health and disease.
2021cited by 19position: contributordoi
The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis.
2021cited by 16position: contributordoi
A Vision for Cytokine Biology with 20/20 Clarity.
2021cited by 1position: contributordoi
T <sub>H</sub> 17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity
Science Immunology 2020cited by 135position: middledoi
Cardiometabolic Traits, Sepsis, and Severe COVID-19
Circulation 2020cited by 129position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2025)Gareth W. Jones · Velindre Cancer Centre7 papers (2019–2023)Valerie B. O’Donnell · Centre for Immunity, Infection and Evolution5 papers (2020–2025)Gareth W. Jones · University of Bristol5 papers (2014–2025)Myles Lewis · University of Córdoba4 papers (2019–2025)Ernest Choy · Cardiff University4 papers (2013–2025)Stephen T. Turner · Monash Institute of Medical Research4 papers (2022–2025)Philip R Taylor · UK Dementia Research Institute4 papers (2019–2023)Ana Cardus Figueras · Institute of Infection and Immunity4 papers (2019–2025)Peter Ghazal · University of Edinburgh3 papers (2016–2025) · 3 papers (2019–2025) · 3 papers (2022–2025)Robert Andrews · Institute of Infection and Immunity3 papers (2022–2025)Barbara Szomolay · Cardiff University3 papers (2022–2025)Ian R. Humphreys · Institute of Infection and Immunity3 papers (2020–2023)Luke Moore · Imperial College Healthcare NHS Trust2 papers (2020–2020)Costantino Pitzalis · Queen Elizabeth Hospital Birmingham2 papers (2014–2025)Luke C. Davies · Cardiff University2 papers (2022–2025)Stefan Rose‐John · Heidelberg University2 papers (2020–2025)Dipender Gill · Nanjing Medical University2 papers (2020–2023)